Petter Bjornstad1, Kara Hughan2, Megan M Kelsey3, Amy S Shah4, Jane Lynch5, Edward Nehus4, Mark Mitsnefes4, Todd Jenkins4, Peixin Xu4, Changchun Xie4, Thomas Inge3, Kristen Nadeau3. 1. University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, CO petter.bjornstad@childrenscolorado.org. 2. University of Pittsburgh and UPMC Children's Hospital Pittsburgh, Pittsburgh, PA. 3. University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, CO. 4. University of Cincinnati, Cincinnati Children's Medical Center, Cincinnati, OH. 5. The University of Texas Health Science Center at San Antonio, San Antonio, TX.
Abstract
OBJECTIVE: To compare diabetic kidney disease (DKD) rates over 5 years of follow-up in two cohorts of severely obese adolescents with type 2 diabetes (T2D) undergoing medical or surgical treatment for T2D. RESEARCH DESIGN AND METHODS: A secondary analysis was performed of data collected from obese participants of similar age and racial distribution enrolled in the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) and the Treatment Options of Type 2 Diabetes in Adolescents and Youth (TODAY) studies. Teen-LABS participants underwent metabolic bariatric surgery (MBS). TODAY participants were randomized to metformin alone or in combination with rosiglitazone or intensive lifestyle intervention, with insulin therapy given for glycemic progression. Glycemic control, BMI, estimated glomerular filtration rate (eGFR), urinary albumin excretion (UAE), and prevalence of hyperfiltration (eGFR ≥135 mL/min/1.73 m2) and elevated UAE (≥30 mg/g) were assessed annually. RESULTS:Participants with T2D from Teen-LABS (n = 30, mean ±SD age, 16.9 ± 1.3 years; 70% female; 60% white; BMI 54.4 ± 9.5 kg/m2) and TODAY (n = 63, age 15.3 ± 1.3 years; 56% female; 71% white; BMI 40.5 ± 4.9 kg/m2) were compared. During 5 years of follow-up, hyperfiltration decreased from 21% to 18% in Teen-LABS and increased from 7% to 48% in TODAY. Elevated UAE decreased from 27% to 5% in Teen-LABS and increased from 21% to 43% in TODAY. Adjusting for baseline age, sex, BMI, and HbA1c, TODAY participants had a greater odds of hyperfiltration (odds ratio 15.7 [95% CI 2.6, 94.3]) and elevated UAE (27.3 [4.9, 149.9]) at 5 years of follow-up. CONCLUSIONS: Compared with MBS, medical treatment of obese youth with T2D was associated with a higher odds of DKD over 5 years.
RCT Entities:
OBJECTIVE: To compare diabetic kidney disease (DKD) rates over 5 years of follow-up in two cohorts of severely obese adolescents with type 2 diabetes (T2D) undergoing medical or surgical treatment for T2D. RESEARCH DESIGN AND METHODS: A secondary analysis was performed of data collected from obeseparticipants of similar age and racial distribution enrolled in the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) and the Treatment Options of Type 2 Diabetes in Adolescents and Youth (TODAY) studies. Teen-LABS participants underwent metabolic bariatric surgery (MBS). TODAY participants were randomized to metformin alone or in combination with rosiglitazone or intensive lifestyle intervention, with insulin therapy given for glycemic progression. Glycemic control, BMI, estimated glomerular filtration rate (eGFR), urinary albumin excretion (UAE), and prevalence of hyperfiltration (eGFR ≥135 mL/min/1.73 m2) and elevated UAE (≥30 mg/g) were assessed annually. RESULTS:Participants with T2D from Teen-LABS (n = 30, mean ± SD age, 16.9 ± 1.3 years; 70% female; 60% white; BMI 54.4 ± 9.5 kg/m2) and TODAY (n = 63, age 15.3 ± 1.3 years; 56% female; 71% white; BMI 40.5 ± 4.9 kg/m2) were compared. During 5 years of follow-up, hyperfiltration decreased from 21% to 18% in Teen-LABS and increased from 7% to 48% in TODAY. Elevated UAE decreased from 27% to 5% in Teen-LABS and increased from 21% to 43% in TODAY. Adjusting for baseline age, sex, BMI, and HbA1c, TODAY participants had a greater odds of hyperfiltration (odds ratio 15.7 [95% CI 2.6, 94.3]) and elevated UAE (27.3 [4.9, 149.9]) at 5 years of follow-up. CONCLUSIONS: Compared with MBS, medical treatment of obese youth with T2D was associated with a higher odds of DKD over 5 years.
Authors: Allan J Collins; Robert N Foley; Charles Herzog; Blanche Chavers; David Gilbertson; Areef Ishani; Bertram Kasiske; Jiannong Liu; Lih-Wen Mau; Marshall McBean; Anne Murray; Wendy St Peter; Haifeng Guo; Sally Gustafson; Qi Li; Shuling Li; Suying Li; Yi Peng; Yang Qiu; Tricia Roberts; Melissa Skeans; Jon Snyder; Craig Solid; Changchun Wang; Eric Weinhandl; David Zaun; Cheryl Arko; Shu-Cheng Chen; Frederick Dalleska; Frank Daniels; Stephan Dunning; James Ebben; Eric Frazier; Christopher Hanzlik; Roger Johnson; Daniel Sheets; Xinyue Wang; Beth Forrest; Edward Constantini; Susan Everson; Paul Eggers; Lawrence Agodoa Journal: Am J Kidney Dis Date: 2011-01 Impact factor: 8.860
Authors: Hans Pottel; Pierre Delanaye; Elke Schaeffner; Laurence Dubourg; Bjørn Odvar Eriksen; Toralf Melsom; Edmund J Lamb; Andrew D Rule; Stephen T Turner; Richard J Glassock; Vandréa De Souza; Luciano Selistre; Karolien Goffin; Steven Pauwels; Christophe Mariat; Martin Flamant; Natalie Ebert Journal: Nephrol Dial Transplant Date: 2017-03-01 Impact factor: 5.992
Authors: Carissa M Baker-Smith; Susan K Flinn; Joseph T Flynn; David C Kaelber; Douglas Blowey; Aaron E Carroll; Stephen R Daniels; Sarah D de Ferranti; Janis M Dionne; Bonita Falkner; Samuel S Gidding; Celeste Goodwin; Michael G Leu; Makia E Powers; Corinna Rea; Joshua Samuels; Madeline Simasek; Vidhu V Thaker; Elaine M Urbina Journal: Pediatrics Date: 2018-08-20 Impact factor: 7.124
Authors: Phil Zeitler; Kathryn Hirst; Laura Pyle; Barbara Linder; Kenneth Copeland; Silva Arslanian; Leona Cuttler; David M Nathan; Sherida Tollefsen; Denise Wilfley; Francine Kaufman Journal: N Engl J Med Date: 2012-04-29 Impact factor: 91.245
Authors: Dana Dabelea; Ronny A Bell; Ralph B D'Agostino; Giuseppina Imperatore; Judith M Johansen; Barbara Linder; Lenna L Liu; Beth Loots; Santica Marcovina; Elizabeth J Mayer-Davis; David J Pettitt; Beth Waitzfelder Journal: JAMA Date: 2007-06-27 Impact factor: 56.272
Authors: Thomas H Inge; Nancy F Krebs; Victor F Garcia; Joseph A Skelton; Karen S Guice; Richard S Strauss; Craig T Albanese; Mary L Brandt; Lawrence D Hammer; Carol M Harmon; Timothy D Kane; William J Klish; Keith T Oldham; Colin D Rudolph; Michael A Helmrath; Edward Donovan; Stephen R Daniels Journal: Pediatrics Date: 2004-07 Impact factor: 7.124
Authors: Abdulghani H Al-Saeed; Maria I Constantino; Lynda Molyneaux; Mario D'Souza; Franziska Limacher-Gisler; Connie Luo; Ted Wu; Stephen M Twigg; Dennis K Yue; Jencia Wong Journal: Diabetes Care Date: 2016-03-22 Impact factor: 19.112
Authors: Petter Bjornstad; Edward Nehus; Todd Jenkins; Mark Mitsnefes; Marva Moxey-Mims; John B Dixon; Thomas H Inge Journal: Kidney Int Date: 2020-02-03 Impact factor: 10.612
Authors: S Christopher Derderian; Luke Patten; Alexander M Kaizer; Jaime M Moore; Sarah Ogle; Todd M Jenkins; Marc P Michalsky; James E Mitchell; Petter Bjornstad; John B Dixon; Thomas H Inge Journal: Obesity (Silver Spring) Date: 2020-12 Impact factor: 5.002
Authors: Jana L Slaght; Brandy Alexandra Wicklow; Allison B Dart; Elizabeth A C Sellers; Melissa Gabbs; Marylin Carino; Jonathan M McGavock Journal: BMJ Open Diabetes Res Care Date: 2021-05
Authors: Petter Bjornstad; Kimberly L Drews; Sonia Caprio; Rose Gubitosi-Klug; David M Nathan; Bereket Tesfaldet; Jeanie Tryggestad; Neil H White; Philip Zeitler Journal: N Engl J Med Date: 2021-07-29 Impact factor: 91.245